Atrial Fibrillation - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Atrial Fibrillation - Pipeline Review, H2 2018’, provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation

- The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects

- The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acesion Pharma Aps

AnaBios Corp

ARCA biopharma Inc

Boston Pharmaceuticals Inc

Correvio Pharma Corp

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

Gilead Sciences ...

Acesion Pharma Aps

AnaBios Corp

ARCA biopharma Inc

Boston Pharmaceuticals Inc

Correvio Pharma Corp

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

Gilead Sciences Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Merck & Co Inc

N-Gene Research Laboratories Inc

Nissan Chemical Industries Ltd

OMEICOS Therapeutics GmbH

The Geneva Biotech Center SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Atrial Fibrillation – Overview

Atrial Fibrillation – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Atrial Fibrillation – Overview

Atrial Fibrillation – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Atrial Fibrillation – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Atrial Fibrillation – Companies Involved in Therapeutics Development

Acesion Pharma Aps

AnaBios Corp

ARCA biopharma Inc

Boston Pharmaceuticals Inc

Correvio Pharma Corp

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

Gilead Sciences Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Merck & Co Inc

N-Gene Research Laboratories Inc

Nissan Chemical Industries Ltd

OMEICOS Therapeutics GmbH

The Geneva Biotech Center SA

Atrial Fibrillation – Drug Profiles

AFC-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-30663 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-105 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGP-15 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-1728515 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bucindolol hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budiodarone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flecainide acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBCA-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Atrial Fibrillation – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-967 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBI-3000 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1832 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIP-151 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-28 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Atrial Fibrillation – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block GIRK for Atrial Fibrillation – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vernakalant hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Atrial Fibrillation – Dormant Projects

Atrial Fibrillation – Discontinued Products

Atrial Fibrillation – Product Development Milestones

Featured News & Press Releases

Jul 17, 2018: OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

Jun 11, 2018: Correvio Provides U.S. Regulatory Update for BRINAVESS

May 18, 2018: LIXIANA (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Hemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organization Conference 2018

May 17, 2018: Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess in China

Apr 27, 2018: Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics

Apr 17, 2018: Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess

Mar 12, 2018: Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation

Feb 08, 2018: Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation

Dec 12, 2017: Espero BioPharma Provides Update on Budiodarone

Nov 15, 2017: New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017

Nov 13, 2017: OMEICOS Announces Formation of Inaugural Clinical Advisory Board

Nov 08, 2017: Daiichi Sankyo Announces New Analyses of Once-Daily SAVAYSA (edoxaban) to be Presented at the 2017 American Heart Association Scientific Sessions

Nov 02, 2017: Cardiome Announces Expansion of Global Geographic Footprint for Brinavess

Oct 06, 2017: Daiichi Sankyo to Install Call Center Support System in Japan Utilizing Artificial Intelligence

Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Atrial Fibrillation, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Atrial Fibrillation, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Atrial Fibrillation – Pipeline by Acesion Pharma Aps, H2 2018

Atrial Fibrillation – Pipeline by AnaBios Corp, H2 2018

Atrial Fibrillation – Pipeline by ARCA biopharma Inc, H2 2018

Atrial Fibrillation – Pipeline by Boston Pharmaceuticals Inc, H2 2018

Atrial Fibrillation – Pipeline by Correvio Pharma Corp, H2 2018

Atrial Fibrillation – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Atrial Fibrillation – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018

Atrial Fibrillation – Pipeline by Gilead Sciences Inc, H2 2018

Atrial Fibrillation – Pipeline by HUYA Bioscience International LLC, H2 2018

Atrial Fibrillation – Pipeline by InCarda Therapeutics Inc, H2 2018

Atrial Fibrillation – Pipeline by Merck & Co Inc, H2 2018

Atrial Fibrillation – Pipeline by N-Gene Research Laboratories Inc, H2 2018

Atrial Fibrillation – Pipeline by Nissan Chemical Industries Ltd, H2 2018

Atrial Fibrillation – Pipeline by OMEICOS Therapeutics GmbH, H2 2018

Atrial Fibrillation – Pipeline by The Geneva Biotech Center SA, H2 2018

Atrial Fibrillation – Dormant Projects, H2 2018

Atrial Fibrillation – Dormant Projects, H2 2018 (Contd..1), H2 2018

Atrial Fibrillation – Dormant Projects, H2 2018 (Contd..2), H2 2018

Atrial Fibrillation – Discontinued Products, H2 2018

Atrial Fibrillation – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Atrial Fibrillation, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Atrial Fibrillation, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports